300
views
0
recommends
+1 Recommend
1 collections
    1
    shares
      scite_
       
      • Record: found
      • Abstract: found
      • Conference Proceedings: found
      Is Open Access

      Health Technology Assessment will make drug repurposing more successful

      Published
      proceedings-article
      1 , , 1 , 1 , 1
      RExPO22
      2-3 September, 2022
      Health Technology Assessment. , , , ., Development-focused HTA,, early HTA, road mapping, value-driven innovation, participatory modelling
      Bookmark

            Abstract

            To ensure successful drug repurposing, determining where a drug can contribute (the most) value is key. The value of a health technology, such as a drug, is not intrinsic, but manifests itself through its use. Health technology assessment (HTA) is “a multidisciplinary process that uses explicit methods to determine the value of a health technology at different points in its lifecycle; the purpose is to inform decision-making in order to promote an equitable, efficient, and high-quality health system” (O’Rourke, 2020). HTA consists of several domains; EUNETHTA, the European Network of HTA agencies, distinguishes between core domains (current use, technical, safety, clinical effectiveness) and other domains (economics, ethics, organization, social and legal). It is important to evaluate these domains in coherence, and with involvement of all relevant stakeholders. Such a participatory approach is increasingly embraced. We propose the use of HTA methods to facilitate value-driven drug repurposing.

            Traditionally, HTA is use-focused. And still, it is predominantly used to make formal decisions regarding the use (and reimbursement) of a health care technology in a specific context. Perhaps HTA is best known for the role the safety, clinical effectiveness and economic domains play in informing decisions about access to (expensive) new drugs in many jurisdictions. But the awareness that HTA should be used to determine value iteratively along the lifecycle of the development of a health care technology is growing. This type of HTA is earlier and the focus is much more on steering development than deciding upon use. It therefore has been labelled development-focused HTA (df-HTA; Bouttel, 2021). It is meant to facilitate value-driven innovation instead of technology-driven innovation. It is also meant to stimulate more efficient innovation, and, in the end, more affordable health care.

            Df-HTA differs from use-focused HTA in a number of ways, and methodologies still need to be further developed. Not in the least because early in the life cycle the reliance on models, and the uncertainty, is high. Df-HTA can be used for horizon scanning, and to prioritize and abandon certain potential use-cases. It can also be used to develop roadmaps for drug development and design the research that will address decision makers’ needs. There are many reasons why drug research may be abandoned or shelved (Krishnamurty, 2022). Df-HTA is can help to remedy a number of these factors. In order for that to be successful, methods need to be improved and made accessible, and the place of df-HTA in health technology innovation, and drug repurposing specifically, needs to be determined and established, together with all stakeholders.

            Content

            Author and article information

            Conference
            30 August 2022
            Affiliations
            [1 ] CAPHRI, Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Center, Maastricht, The Netherlands
            Article
            10.14293/S2199-rexpo22013.v1
            0984e88e-5db5-4f5a-94b1-865ad77c2835
            The Authors

            Published under Creative Commons Attribution 4.0 International ( CC BY 4.0). Users are allowed to share (copy and redistribute the material in any medium or format) and adapt (remix, transform, and build upon the material for any purpose, even commercially), as long as the authors and the publisher are explicitly identified and properly acknowledged as the original source.

            RExPO22
            Maastricht, Netherlands
            2-3 September, 2022
            History
            Product

            ScienceOpen


            Data sharing not applicable to this article as no datasets were generated or analysed during the current study.
            Pharmacology & Pharmaceutical medicine
            participatory modelling,value-driven innovation,road mapping,early HTA,Development-focused HTA,,Health Technology Assessment. , , , .

            References

            1. O'Rourke Brian, Oortwijn Wija, Schuller Tara. The new definition of health technology assessment: A milestone in international collaboration. International Journal of Technology Assessment in Health Care. Vol. 36(3):187–190. 2020. Cambridge University Press (CUP). [Cross Ref]

            2. Bouttell Janet, Briggs Andrew, Hawkins Neil. The thorny issue of value alignment: how development-focused health technology assessment can help find win–win situations for patients and healthcare systems and commercial investors. International Journal of Technology Assessment in Health Care. Vol. 37(1)2021. Cambridge University Press (CUP). [Cross Ref]

            3. Krishnamurthy Nithya, Grimshaw Alyssa A., Axson Sydney A., Choe Sung Hee, Miller Jennifer E.. Drug repurposing: a systematic review on root causes, barriers and facilitators. BMC Health Services Research. Vol. 22(1)2022. Springer Science and Business Media LLC. [Cross Ref]

            Comments

            Comment on this article